national
FDA Advisory Panel Recommends Restrictions on Compounded Peptides
Just the facts
The Pharmacy Compounding Advisory Committee reviewed multiple bulk drug substances to determine their suitability for custom pharmacy compounding. The committee's recommendation to limit these substances could significantly impact wellness clinics and compounding pharmacies that distribute peptides for anti-aging and athletic recovery. Industry representatives argued that the restrictions would restrict patient access to widely used therapies. The FDA will review the panel's advisory votes before implementing any final regulatory changes.
Why this is news
A Food and Drug Administration advisory panel voted to recommend restricting the compounding of several popular peptides, citing safety and efficacy concerns.
Sources
This summary is compiled strictly from the original reporting below.